Pharmacoeconomic evaluations of netupiptant/palonosetron in preventing carboplatin chemotherapy-related nausea and vomiting under diagnosis-related group payment
OBJECTIVE To provide references for rational use of netupitant/palonosetron in chemotherapy-induced nausea and vomiting(CINV)and implement refined in-hospital management of diagnosis-related group(DRG)drugs.METHODS From May 1,2022 to February 28,2023,164 cases were enrolled at Jiangsu Cancer Hospital with a code of RE 13(chemotherapy and/or other treatments for malignant proliferative diseases with concurrent conditions or complications)and RG13(targeting and immunotherapy for malignant proliferative diseases with concurrent conditions or complications).Group A received fosaprepitant dimeglumine,palonosetron and dexamethasone(n=128)while Group B was subjected to a prophylactic regimen of netupitant/palonosetron and dexamethasone(n=36).Clinical efficacy and adverse reactions were compared,treatment expenses calculated and pharmacoeconomic evaluations conducted for two treatment protocols.And sensitivity analysis was performed simultane-ously.RESULTS No statistically significant inter-group difference existed in clinical efficacy or adverse reactions(P＞0.05).The expenses of groups A and B were 2 017.911 and 1 575.751 yuan respectively.Treatment protocol was more economical for group B.The above conclusion was supported by the results of sensitivity analysis.CONCLUSION"Netupitant/palonosetron plus dexamethasone"and"fosaprepitant plus palonosetron plus dexamethasone"offer comparable efficacy and safety in the preven-tion of carboplatin CINV.The former is more cost-effective than the latter.It is indicated for patients with dysphagia unsuitable for oral antiemetics.To provide references for rational use of netupitant/palonosetron in chemotherapy-induced nausea and vomit-ing(CINV)and implement refined in-hospital management of diagnosis-related group(DRG)drugs.
diagnosis-related groupnetupitant/palonosetroncarboplatinchemotherapy-related nausea and vomitingpharmacoeconomics
NETL
NSTL
万方数据
